David Boyer, MD
Dr. Boyer is a world-renowned clinician, surgeon and educator. He received a B.S. from the University of Illinois at Champaign, after which he completed a medical degree at the Chicago Medical School. In 1976 he finished his residency at the U.S.C. County Medical Center. A year long retinal surgery fellowship at the Wills Eye Hospital, located in Philadelphia, completed his training. He is currently a leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple research, educational and charitable institutions.
Geeta Lalwani, MD
Dr. Lalwani is the founder of Rocky Mountain Retina Associates, where she specializes in the medical and surgical treatment of retinal diseases. Prior to Rocky Mountain Retina, Dr. Lalwani was with the University of Miami’s prestigious Bascom Palmer Eye Institute as an Assistant Professor of Clinical Ophthalmology. Dr. Lalwani has published extensively in numerous areas including macular degeneration and diabetic retinopathy, and has been an investigator in a number of landmark clinical studies including PRONTO, SAILOR and HORIZON. Dr. Lalwani completed her fellowship in vitreoretinal surgery at the Bascom Palmer Eye Institute, completed her ophthalmology residency at Case Western Reserve, and received her M.D. from Drexel University. Dr. Lalwani is Board Certified by the American Board of Ophthalmology. She is an active member of the American Academy of Ophthalmologists, American Society of Retina Specialists, the Vit-Buckle Society and the esteemed Retina Society.
Neena Haider, PhD
Dr. Haider has been involved in the field of genetics and retinal disease for more than 15 years. She aims to identify key genetic factors that modulate inherited retinal diseases, and she investigates the influence of genes on the multipotency of neural stem cells and retinal progenitors. She also develops and tests therapeutic targets for retinal degenerations (including AMD and diabetic retinopathy). She recently identified a genetic modifier that is able to ameliorate more than one form of inherited retinal degeneration, and has developed several unique genetic models to study the retinal and vascular phenotypes associated with macular degeneration. Dr. Haider is an Associate Professor of Ophthalmology at Harvard Medical School and an Associate Scientist at Schepens Eye Research Institute. She completed her Ph.D. in Genetics at the University of Iowa and her postdoctoral fellowship at Jackson Laboratory in Bar Harbor, Maine.
Timothy T. McMahon, OD, FAAO
Dr. McMahon graduated from Illinois College of Optometry in 1980 and completed his residency at the Kansas City Veterans Administration Medical Center. He is presently Vice Chair for Optometry and professor of ophthalmology at the University of Illinois at Chicago Department of Ophthalmology & Visual Sciences. Dr. McMahon is active in his field, serving as the secretary/treasurer of the American Academy of Optometry Board of Directors, secretary of the LRS Committee of the World Council of Optometry and President of the World Optometry Foundation. He is Fellow of the American Academy of Optometry and is a Diplomate in the Section on Cornea, Contact Lenses and Refractive Technologies. In 2000 the National Academies of Practice named him a Distinguished Clinical Fellow. He has published widely and has lectured nationally and internationally.
Michael E. Stern, PhD
Michael E. Stern, PhD, is Chief Scientific Officer at ImmunEyeZ, LLC. He is also the co-director of the Ocular Immunology at IOBA (University of Valladolid) and Adjunct Associate Professor at Baylor College of Medicine. During his 26 year tenure at Allergan, Dr. Stern led an effort elucidating the pathophysiology of Dry Eye. This laboratory was key in defining this disease as a immune based inflammation of the Lacrimal Functional Unit. Further research defined the role of T-helper cells, T-regulatory cells, Dendritic Cells and B-cells in the initiation and maintenance of this chronic immune pathology. Additionally, Dr. Stern's laboratory helped to define the role of cyclosporine as a therapeutic in this T-cell based disease which contributed to the development and approval of Restasis. Dr. Stern has authored over 100 publications, 300 abstracts and several book chapters. Additionallyl, along with Dr. Stephen Pflugfelder and Dr. Roger Beuerman, he published a book: Dry Eye and Ocular Surface Disorders (2004). Dr. Stern serves on the editorial board of Investigative Ophthalomology (IOVS), The Ocular Surface, and Journal of Ocular Pharmaceutics and Therapeutics.